Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

TCGA-BH-A0H6-01A-21R-A056-07

— · A

ed9b5e4f-2973-5e6f-b842-5fcdbbd40f33

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
A
subtype
A
overall_survival_months
25
os_event
false

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.420
  • UV_RESPONSE_DN+0.380
  • ESTROGEN_RESPONSE_EARLY+0.370
  • TGF_BETA_SIGNALING+0.320
  • ANGIOGENESIS+0.300
  • HEDGEHOG_SIGNALING+0.280
  • MYOGENESIS+0.280
  • ESTROGEN_RESPONSE_LATE+0.270
  • CHOLESTEROL_HOMEOSTASIS+0.240
  • ANDROGEN_RESPONSE+0.230

Top 10 suppressed

  • ALLOGRAFT_REJECTION-0.500
  • INTERFERON_ALPHA_RESPONSE-0.500
  • E2F_TARGETS-0.470
  • INTERFERON_GAMMA_RESPONSE-0.450
  • G2M_CHECKPOINT-0.440
  • IL6_JAK_STAT3_SIGNALING-0.310
  • COMPLEMENT-0.210
  • INFLAMMATORY_RESPONSE-0.200
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.170
  • IL2_STAT5_SIGNALING-0.160

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
120020054.LumA
breast-umap@18
—A0.863
220060260.Her2HRpos
breast-umap@18
—A0.836
320020070.LumA
breast-umap@18
—A0.827
4TCGA-S3-AA14-01A-11R-A41B-07
breast-umap@18
—A0.821
5TCGA-A8-A06P-01A-11R-A00Z-07
breast-umap@18
—A0.807
6TCGA-A2-A0EM-01A-11R-A034-07
breast-umap@18
—B0.805
7TCGA-A1-A0SG-01A-11R-A144-07
breast-umap@18
—A0.801
820030017.LumA
breast-umap@18
—B0.781
9TCGA-AN-A0FS-01A-11R-A034-07
breast-umap@18
—A0.781
10TCGA-B6-A1KI-01A-11R-A14M-07
breast-umap@18
—B0.780

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 27 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.420Inavolisib— uncovered
UV_RESPONSE_DN0.380Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.370Inavolisib— uncovered
TGF_BETA_SIGNALING0.320Inavolisib— uncovered
ANGIOGENESIS0.300Remibrutinib— uncovered
HEDGEHOG_SIGNALING0.280Inavolisib— uncovered
MYOGENESIS0.280Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.270Idelalisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.240Remibrutinib— uncovered
ANDROGEN_RESPONSE0.230Inavolisib— uncovered
ADIPOGENESIS0.220Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.220Remibrutinib— uncovered
APICAL_JUNCTION0.170Inavolisib— uncovered
PROTEIN_SECRETION0.160Remibrutinib— uncovered
APICAL_SURFACE0.140Temsirolimus— uncovered
P53_PATHWAY0.140Idelalisib— uncovered
FATTY_ACID_METABOLISM0.130Inavolisib— uncovered
HEME_METABOLISM0.130Temsirolimus— uncovered
TNFA_SIGNALING_VIA_NFKB0.110Inavolisib— uncovered
MYC_TARGETS_V20.090Idelalisib— uncovered